New Mechanisms for Vascular Control of Inflammation Mediated by Natural Anticoagulant Proteins by Esmon, Charles T.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/09/561/4 $5.00
Volume 196, Number 5, September 2, 2002 561–564
http://www.jem.org/cgi/doi/10.1084/jem.20021088
 
Commentary
 
561
 
New Mechanisms for Vascular Control of Inﬂammation 
Mediated by Natural Anticoagulant Proteins
 
Charles T. Esmon
 
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Department of Pathology and 
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, and Howard 
Hughes Medical Institute, Oklahoma City, OK 73104
 
It has been appreciated for a very long time that infec-
tions, particularly bacterial infections of the blood leading
to severe sepsis, trigger a hypercoaguable state that some-
times leads to overt disseminated intravascular coagulation.
We now recognize that endotoxins and other bacterial,
fungal, and viral products can activate the toll receptors,
leading to the elaboration of inflammatory cytokines (1)
that in turn elicit tissue factor expression to trigger the
blood clotting process (2). More recently, we have begun
to appreciate the critical role played by natural anticoagu-
lants in controlling the processes leading to septic shock (3).
Of these natural anticoagulants, the protein C anticoagulant
pathway seems to play a particularly important role in
dampening the inflammatory response that occurs with en-
dotoxin and bacteremia. It has now become clear that
many of the components in the pathway possess multiple
activities that contribute to the regulation of a variety of
anticoagulant and antiinflammatory functions. The path-
way is illustrated in Fig. S1 (available at http://www.
jem.org/cgi/content/full/jem.20021088/DC1). A key fea-
ture of the pathway involves protein C activation on the
vascular endothelial cell surface leading to the formation of
activated protein C (APC). The activation complex is
composed of thrombin and protein C bound respectively
to the endothelial cell proteins, thrombomodulin (TM) and
the endothelial cell protein C receptor (EPCR; references
4–6). APC was originally recognized as an anticoagulant
 
that worked by the proteolytic inactivation of factors Va and
VIIIa, thereby shutting down thrombin formation (7, 8). In
addition to its anticoagulant activity, APC also possesses
antiinflammatory properties. APC is known to inhibit the
release of inflammatory cytokines such as tumor necrosis
factor 
 
  
 
in experimental animals challenged with endo-
toxin (9, 10). APC also limits leukocyte adhesion (11) and
protects against an endotoxin-induced decrease in blood
pressure (12). At least some of these activities are thought
to be due to the ability of APC to inhibit nuclear factor 
 
 
 
B
 
nuclear translocation (13) and reduce nuclear factor 
 
 
 
B
mRNA levels (14). The multifunctional nature of APC
probably accounts for its ability to decrease the death rate in
experimental animals (12) and patients (15) with severe sepsis.
Recently, attention has begun to shift toward under-
standing new functions of the protein C activation com-
plex. Like APC, EPCR appears to have antiinflammatory
activities. EPCR can be shed from the endothelium by an
inducible metalloproteinase (16). Soluble EPCR binds to
proteinase 3, an elastase-like enzyme, and this complex can
bind to the adhesion integrin CD11b/CD18 (17). The
EPCR–APC complex also seems to be important in pre-
venting leukocyte infiltration into tissues (18). Further-
more, several of the antiinflammatory activities of APC
seem to be mediated through APC binding to EPCR (19).
A new potential role for soluble EPCR was suggested by
the recent solution of the crystal structure (20). EPCR was
shown to be remarkably similar in structure to the MHC
class 1/CD1 family of proteins, most of which are involved
in inflammatory processes. The CD1 family are known to
bind lipid antigens and present them to T cells (21, 22).
This process seems to be important in host defense against
infection. Like the CD1 family, EPCR binds a lipid, in this
case a phospholipid, in the groove used by CD1 family
members for lipid antigen presentation, which suggests by
extrapolation that EPCR may also have a function in lipid
antigen presentation (20).
In this issue, Conway et al. (23) provide evidence for
one additional and important antiinflammatory activity of
the pathway, TM-dependent inhibition of leukocyte adhe-
sion to activated endothelium. TM is a complex membrane
protein with a lectin-like domain from the amino terminus,
six epidermal growth factor (EGF)-like repeats, a region
with O-linked sugar addition sites that also contains the
sites for the addition of chondroitin sulfates, a transmem-
brane domain, and a short cytoplasmic tail. The thrombin
binding site required for rapid protein C activation resides
in EGF repeats 4–6 (24). Binding of thrombin to this site
not only accelerates protein C activation about 100-fold,
but also blocks the ability of thrombin to clot fibrinogen
and participate in platelet and endothelial cell activation
(25). An additional role of TM is to accelerate thrombin
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activation of a plasma procarboxypeptidase B (26). When
activated, this class of enzymes removes carboxy terminal
arginine and lysine residues. It was originally thought that
this enzyme’s major target might be fibrin, where removal
of lysine residues results in resistance to clot lysis (26).
Hence, the enzyme is commonly referred to as thrombin
activatable fibrinolysis inhibitor (TAFI). More recently,
however, it has been shown that TAFI is probably the pri-
mary enzyme responsible for inactivation of the comple-
ment-derived anaphylatoxin, C5a (27). Given the high ef-
fective TM concentration in the microcirculation (25), the
rapid TAFI activation and subsequent rapid inactivation of
C5a would be expected to protect against complement-
mediated injury to the microcirculation.
Because thrombin activation of endothelial cells contrib-
utes to a variety of inflammatory events including the ex-
pression of P selectin on the endothelial cell surface and the
formation of the neutrophil agonist, platelet-activating fac-
tor (28), the ability of TM to block these activities has an
indirect antiinflammatory effect. Furthermore, binding
thrombin to TM dramatically increases the rate at which
thrombin is neutralized by plasma proteinase inhibitors
(29). Once neutralized, the thrombin inhibitor complex
dissociates from TM. Other functions for TM have also
been suggested, including thrombin internalization and
degradation (30) and the ability of the EGF repeat regions
to stimulate fibroblast growth (31). Until now, however,
no function had been identified for the lectin-like domain
of TM. In the report by Conway et al. (23) in this issue,
they not only show that deletion of the lectin domain from
TM in mice increases leukocyte infiltration in a variety of
experimental conditions, but also demonstrate that the iso-
lated soluble domain possesses this function. The lectin do-
main, whether soluble or as part of intact cellular TM, pro-
vides protection against systemic and inhaled endotoxin,
and ischemia/reperfusion injury. At least in part, these ac-
tivities appear to be mediated by the suppression of the mi-
togen-activated protein kinase pathway. These exciting re-
sults not only suggest a novel role for TM and an
interesting new therapeutic candidate for the treatment of
acute inflammatory diseases, but they also help to explain
some of the interesting results seen when TM expression is
altered in vivo.
As discussed above, the protein C anticoagulant pathway
limits the expression of inflammatory mediators and damp-
ens leukocyte extravasation into the tissues. However, the
pathway is not static. Inflammatory cytokines can down-
regulate TM and EPCR expression by inhibiting gene
transcription and in the case of EPCR, by promoting
shedding from the endothelium. When neutrophils are
bound to the endothelium and become activated, they re-
lease potent oxidants that reduce the ability of TM to bind
thrombin and activate protein C (32). They also release
proteases that can proteolytically remove TM from the en-
dothelium (33, 34) with the released form being much less
active than the endothelial cell form. TM expression is also
subject to down-regulation by fluid shear force (35). As a
result of these and potentially other mechanisms for regu-
 
lating expression, the protein C activation complex can be
impaired in a variety of clinically relevant situations. In a
subset of patients with severe sepsis, TM expression on the
vasculature is down-regulated, leading to decreased protein
C activation (36). The loss of direct activities targeted to-
ward inhibiting leukocyte extravasation would further
compromise the already damaged and fragile vasculature in
these patients.
Another example of TM down-regulation is in Wege-
ner’s granulomatosis (37). Here, leukocyte infiltrates in
the vasculature are prevalent. The plot thickens, how-
ever, as the autoantibodies are thought to target protein-
ase 3 in particular. Proteinase 3 is the molecule through
which EPCR binds to the activated leukocyte surface
(17). It would seem likely that in some vascularities, both
compromised TM expression and impaired interaction
with EPCR would contribute to the progression of the
disease.
Atherosclerotic plaque development is another situation
in which the protein C system could play an important
role. The expression of both TM and EPCR is dramatically
reduced on endothelium overlying atherosclerotic plaque
in humans (38), suggesting reduced protein C activation in
these areas. Based on the studies presented herein by Con-
way et al (23) and the other studies reviewed above, the
decreased expression would be anticipated to facilitate leu-
kocyte attachment and possibly infiltration into the ather-
oma. In turn, this could contribute to the growth of the
atheroma, the fragility of the fibrous cap, and the thrombo-
genicity of the ruptured plaque.
Direct examples of important roles for TM therapies and
disease processes involving the heart have begun to emerge.
In model systems, TM overexpression has been shown to
prevent thrombosis, leukocyte infiltration, and restenosis in
rabbit systems involving deep arterial injury (39). Although
some of the inhibition of leukocyte infiltration seen in this
system is likely due to APC formation, the presence of in-
creased concentrations of direct leukocyte inhibitory activ-
ity related to the increased expression of TM probably also
played a significant role and could have been the dominant
contribution responsible for preventing the restenosis. In
vein bypass grafts, recent studies have shown that TM
down-regulation occurs within days after graft placement
and likely contributes to the thrombotic complications that
ensue (40). Loss of the leukocyte inhibitory functions of
TM seems likely to contribute to both the thrombosis and
restenosis that is prevalent in these grafts.
The report in this issue by Conway et al (23) adds an
important new insight into the control of the inflamma-
tory process by the protein C anticoagulant pathway spe-
cifically, and the role of the vasculature in general. In
particular, it provides greater insights into the patho-
physiological sequelae that follow the down-regulation of
TM in a variety of common, clinically relevant situations.
Given the rapid rate of new discoveries of the roles of the
protein C pathway in the regulation of inflammation, it
seems likely that many more novel mechanisms involving
this pathway will be identified in the near future and this is 
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likely to be followed by the application of these findings to
new therapies.
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